Adveq Opportunity is a private equity general partner firm headquartered in New York, NY, United States.
Global fund-of-funds Adveq is to be bought by Schroders, a UK-listed asset manager, and will be renamed Schroder Adveq.
Biopharmaceutical company Second Genome closed a $42.6m Series B investment round led by Pfizer Venture Investment and Roche Venture Fund.
Adveq has promoted Farah Buckley, Richard Damming, Matt Ma Chang, Daniel Rhoads, Nico Taverna and Ethan Vogelhut to Executive Directors.
Read more news concerning Adveq Opportunity
A sampling of Adveq Opportunity portfolio companies:
View all of the investments in their portfolio
This firm also pursues other investment strategies:
Registration is fast, free and easy
Already a member?